Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleState of the Art

Fibroblast Activation Protein Inhibitor–Based Radionuclide Therapies: Current Status and Future Directions

Manish Ora, Neetu Soni, Aftab Hasan Nazar, Manish Dixit, Rohit Singh, Savita Puri, Michael M. Graham and Sanjay Gambhir
Journal of Nuclear Medicine June 2023, jnumed.123.265594; DOI: https://doi.org/10.2967/jnumed.123.265594
Manish Ora
1Department of Nuclear Medicine, SGPGIMS, Lucknow, India;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neetu Soni
2Department of Radiology, University of Rochester Medical Center, Rochester, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aftab Hasan Nazar
1Department of Nuclear Medicine, SGPGIMS, Lucknow, India;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manish Dixit
1Department of Nuclear Medicine, SGPGIMS, Lucknow, India;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rohit Singh
3Division of Hematology–Oncology, University of Vermont Medical Center, Burlington, Vermont; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Savita Puri
2Department of Radiology, University of Rochester Medical Center, Rochester, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael M. Graham
4Division of Nuclear Medicine, Department of Radiology, University of Iowa Health Care, Iowa City, Iowa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay Gambhir
1Department of Nuclear Medicine, SGPGIMS, Lucknow, India;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

jnumed.123.265594
DOI 
https://doi.org/10.2967/jnumed.123.265594
PubMed 
37268422

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication February 13, 2023
  • Revision received March 30, 2023
  • Published online June 2, 2023.

Article Versions

  • You are currently viewing a previous version of this article (June 2, 2023 - 11:47).
  • View the most recent version of this article
Copyright & Usage 
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Manish Ora*,1,
  2. Neetu Soni*,2,
  3. Aftab Hasan Nazar1,
  4. Manish Dixit1,
  5. Rohit Singh3,
  6. Savita Puri2,
  7. Michael M. Graham4 and
  8. Sanjay Gambhir1
  1. 1Department of Nuclear Medicine, SGPGIMS, Lucknow, India;
  2. 2Department of Radiology, University of Rochester Medical Center, Rochester, New York;
  3. 3Division of Hematology–Oncology, University of Vermont Medical Center, Burlington, Vermont; and
  4. 4Division of Nuclear Medicine, Department of Radiology, University of Iowa Health Care, Iowa City, Iowa
  1. For correspondence or reprints, contact Manish Ora (drmanishora{at}yahoo.com).
  1. ↵* Contributed equally to this work.

View Full Text

Statistics from Altmetric.com

Cited By...

  • 18 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • FAPi-Based Agents in Thyroid Cancer: A New Step towards Diagnosis and Therapy? A Systematic Review of the Literature
    Priscilla Guglielmo, Pierpaolo Alongi, Lucia Baratto, Miriam Conte, Elisabetta Maria Abenavoli, Ambra Buschiazzo, Greta Celesti, Francesco Dondi, Rossella Filice, Joana Gorica, Lorenzo Jonghi-Lavarini, Riccardo Laudicella, Maria Librando, Flavia Linguanti, Francesco Mattana, Alberto Miceli, Laura Olivari, Leandra Piscopo, Giulia Santo, Fabio Volpe, Laura Evangelista
    Cancers 2024 16 4
  • Small Molecule‐Drug Conjugates: Opportunities for the Development of Targeted Anticancer Drugs
    Jingjing Zhang, Fanchun Hu, Omer Aras, Yichao Chai, Feifei An
    ChemMedChem 2024 19 11
  • Fibroblast Activation Protein Inhibitor (FAPI) PET Imaging in Sarcomas: A New Frontier in Nuclear Medicine
    Francesco Giammarile, Peter Knoll, Diana Paez, Enrique Estrada Lobato, Adriana K. Calapaquí Terán, Roberto C. Delgado Bolton
    Seminars in Nuclear Medicine 2024 54 3
  • Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?
    Rubel Chakravarty, Wenyu Song, Sudipta Chakraborty, Weibo Cai
    European Journal of Nuclear Medicine and Molecular Imaging 2023 50 10
  • Autophagy inhibition improves the targeted radionuclide therapy efficacy of 131I-FAP-2286 in pancreatic cancer xenografts
    Xingyu Liu, Danni Li, Tianbao Ma, Xiu Luo, Ye Peng, Tao Wang, Changjing Zuo, Jianming Cai
    Journal of Translational Medicine 2024 22 1
  • Development of fibroblast activation protein-α radiopharmaceuticals: Recent advances and perspectives
    Ziyue Yu, Zeng Jiang, Xuebo Cheng, Leilei Yuan, Hualong Chen, Lin Ai, Zehui Wu
    European Journal of Medicinal Chemistry 2024 277
  • 211At radiolabeled APBA-FAPI for enhanced targeted-alpha therapy of glioma
    Tianzhen Ye, Yuying Yu, Guofeng Qu, Huan Ma, Shilong Shi, Jiujian Ji, Jie Lyu, Yuanyou Yang, Ning Liu, Feize Li
    European Journal of Medicinal Chemistry 2024 279
  • Clinical and research applications of fibroblast activation protein-α inhibitor tracers: a review
    Mélanie Desaulniers, Étienne Rousseau, Kim M Pabst
    British Journal of Radiology 2025
  • The cutting edge: Promising oncology radiotracers in clinical development
    Jorge D. Oldan, Martin G. Pomper, Rudolf A. Werner, Takahiro Higuchi, Steven P. Rowe
    Diagnostic and Interventional Imaging 2024 105 10
  • [64Cu]Cu-FAP-NOX, a N-oxalyl modified cyclic peptide for FAP PET imaging with a flexible imaging time window
    Shaoyu Liu, Jiawei Zhong, Ziqi Zhang, Ruiyue Zhao, Qingsong Yan, Xinlu Wang
    European Journal of Nuclear Medicine and Molecular Imaging 2024 51 12

Article usage

Article usage: June 2023 to April 2025

AbstractFullPdf
Jun 20232460193132
Jul 20233044243206
Aug 202397711457
Sep 2023129396113
Oct 2023122301140
Nov 202387251101
Dec 20238119194
Jan 2024111321177
Feb 202469343125
Mar 202477372144
Apr 202465494163
May 202476222145
Jun 202466309176
Jul 202450380152
Aug 202440307137
Sep 20244117683
Oct 202450288138
Nov 202456342137
Dec 202422324209
Jan 202533245142
Feb 202556234143
Mar 202544213105
Apr 202530268125
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (5)
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Fibroblast Activation Protein Inhibitor–Based Radionuclide Therapies: Current Status and Future Directions
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Fibroblast Activation Protein Inhibitor–Based Radionuclide Therapies: Current Status and Future Directions
Manish Ora, Neetu Soni, Aftab Hasan Nazar, Manish Dixit, Rohit Singh, Savita Puri, Michael M. Graham, Sanjay Gambhir
Journal of Nuclear Medicine Jun 2023, jnumed.123.265594; DOI: 10.2967/jnumed.123.265594

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Fibroblast Activation Protein Inhibitor–Based Radionuclide Therapies: Current Status and Future Directions
Manish Ora, Neetu Soni, Aftab Hasan Nazar, Manish Dixit, Rohit Singh, Savita Puri, Michael M. Graham, Sanjay Gambhir
Journal of Nuclear Medicine Jun 2023, jnumed.123.265594; DOI: 10.2967/jnumed.123.265594
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • NONTUMOR COMPONENT OF CANCER
    • TARGETING OF CAFS AS AN ANTITUMOR TREATMENT (Fig. 2)
    • PRELIMINARY RESULTS ON FAPI-BASED RADIONUCLIDE THERAPY
    • CHALLENGES AHEAD AND POTENTIAL AREAS OF FUTURE RESEARCH
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Quantitative Brain Amyloid PET
  • The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease
  • Sequencing of Somatostatin-Receptor–Based Therapies in Neuroendocrine Tumor Patients
Show more State of the Art

Similar Articles

Keywords

  • cancer-associated fibroblasts
  • fibroblast activation protein
  • radionuclide therapy
  • PET/CT
  • cancer management
  • FAPI
SNMMI

© 2025 SNMMI

Powered by HighWire